KCM
HZNP

Kingdon Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Kingdon Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,959,258
Closed -$43.7M – 150
2017
Q1 		$43.7M Sell
2,959,258
-3,723,360
-56% -$60.3M 2.4% 7
2016
Q4 		$108M Sell
6,682,618
-134,285
-2% -$2.44M 5.23% 1
2016
Q3 		$124M Buy
6,816,903
+2,761,736
+68% +$54M 5.67% 3
2016
Q2 		$66.8M Buy
4,055,167
+2,878,892
+245% +$46.6M 3.67% 5
2016
Q1 		$19.5M Sell
1,176,275
-1,343,680
-53% -$23.5M 1.07% 29
2015
Q4 		$54.6M Buy
2,519,955
+1,270,321
+102% +$24.7M 2.66% 8
2015
Q3 		$24.8M Sell
1,249,634
-2,076,195
-62% -$65.6M 1.19% 22
2015
Q2 		$116M Sell
3,325,829
-371,311
-10% -$11.3M 4.52% 2
2015
Q1 		$96M Sell
3,697,140
-2,377,476
-39% -$43.6M 4.07% 3
2014
Q4 		$78.3M Buy
6,074,616
+3,927,012
+183% +$49.2M 3.4% 4
2014
Q3 		$26.4M Buy
2,147,604
+91,520
+4% +$1.06M 1.18% 19
2014
Q2 		$32.5M Buy
2,056,084
+23,720
+1% +$339K 1.25% 12
2014
Q1 		$30.7M Buy
2,032,364
+533,085
+36% +$6.02M 1.57% 10
2013
Q4 		$11.4M Buy
1,499,279
+325,551
+28% +$1.76M 0.52% 60
2013
Q3 		$3.96M Buy
1,173,728
+425,100
+57% +$1.12M 0.19% 136
2013
Q2 		$1.84M Buy
+748,628
New +$1.8M 0.11% 169

Other funds holding HZNP

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Kingdon Capital Management's HZNP Position: Q2 2017 in Review

Kingdon Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2017, closing a stake of 2,959,258 shares — an estimated $43.7M sold.

Kingdon Capital Management first reported a position in HZNP in Q2 2013 and held it in 16 quarters. The position peaked at $124M in Q3 2016. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

  • Kingdon Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • Kingdon Capital Management sold 2,959,258 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $43.7M.
  • Kingdon Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 16 quarters.
  • Kingdon Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $124M in Q3 2016.
  • 190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on Kingdon Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.